<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01135446</url>
  </required_header>
  <id_info>
    <org_study_id>MB102-088</org_study_id>
    <nct_id>NCT01135446</nct_id>
  </id_info>
  <brief_title>Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy Subjects</brief_title>
  <acronym>ULDS</acronym>
  <official_title>Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacodynamics (PD), pharmacokinetics (PK),
      safety and tolerability following single oral doses of 0.001 mg to 2.5 mg dapagliflozin in
      healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total 24-hour Urinary Glucose Excretion as a Measure of Pharmacodynamic Effect</measure>
    <time_frame>24 hours after dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>24 hours after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dapagliflozin and Dapagliflozin 3-O-glucuronide (Metabolite of Dapagliflozin) Concentrations to Characterize Dapagliflozin Pharmacokinetics</measure>
    <time_frame>2 days after dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>dapagliflozin (0.001 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dapagliflozin (0.01 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dapagliflozin (0.1 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dapagliflozin (0.3 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dapagliflozin (1 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dapagliflozin (2.5 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 6</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dapagliflozin</intervention_name>
    <description>Oral Solution, Oral, 0.001 mg, once on Day 1 only, 2 days</description>
    <arm_group_label>dapagliflozin (0.001 mg)</arm_group_label>
    <other_name>BMS-512148</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dapagliflozin</intervention_name>
    <description>Oral Solution, Oral, 0.01 mg, once on Day 1 only, 2 days</description>
    <arm_group_label>dapagliflozin (0.01 mg)</arm_group_label>
    <other_name>BMS-512148</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dapagliflozin</intervention_name>
    <description>Oral Solution, Oral, 0.1 mg, once on Day 1 only, 2 days</description>
    <arm_group_label>dapagliflozin (0.1 mg)</arm_group_label>
    <other_name>BMS-512148</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dapagliflozin</intervention_name>
    <description>Tablets, Oral, 0.3 mg, once on Day 1 only, 2 days</description>
    <arm_group_label>dapagliflozin (0.3 mg)</arm_group_label>
    <other_name>BMS-512148</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dapagliflozin</intervention_name>
    <description>Tablets, Oral, 1 mg, once on Day 1 only, 2 days</description>
    <arm_group_label>dapagliflozin (1 mg)</arm_group_label>
    <other_name>BMS-512148</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dapagliflozin</intervention_name>
    <description>Tablets, Oral, 2.5 mg, once on Day 1 only, 2 days</description>
    <arm_group_label>dapagliflozin (2.5 mg)</arm_group_label>
    <other_name>BMS-512148</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy men and women

          -  WOCBP who are using acceptable method of contraception

          -  Women who are not nursing

        Exclusion Criteria:

          -  History of GI disease

          -  Any GI surgery that could impact study drug absorption

          -  Glucosuria at screening or Day -2

          -  Abnormal liver function tests (ALT, AST or total bilirubin &gt; 10% above ULN)

          -  History of current or recurrent UTI

          -  History of Diabetes Mellitus

          -  History of chronic or recurrent vulvovaginal mycotic infections

          -  Estimated creatinine clearance (ClCr) &lt; 80 mL/min using Cockroft-Gault formula

          -  History of allergy to SGLT2 inhibitors or related compounds
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ppd Development, Lp</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=3653&amp;filename=MB102-088_redacted_CSR_synopsis.pdf</url>
    <description>MB102-088_redacted_CSR_synopsis</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2010</study_first_submitted>
  <study_first_submitted_qc>June 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2010</study_first_posted>
  <last_update_submitted>October 14, 2016</last_update_submitted>
  <last_update_submitted_qc>October 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

